Flavivirus vaccine

Patent metadata

Field	Value
Publication number	US-11931406-B2
Application number	US-201816772131-A
Country	US
Kind code	B2
Filing date	Dec 12, 2018
Priority date	Dec 13, 2017
Publication date	Mar 19, 2024
Grant date	Mar 19, 2024

Abstract

The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptide, composition, in particular the first and second medical uses of the immunogenic composition according to the invention.

First claim

The invention claimed is:

1. A pharmaceutical formulation comprising RNA formulated in a lipid nanoparticle (LNP), said RNA comprising
a) at least one coding region encoding at least one polypeptide comprising a flavivirus premembrane protein (prM) and a flavivirus envelope protein (E), wherein the at least one coding region comprises a nucleic acid sequence at least 95% identical to the coding sequence of SEQ ID NO: 2630, and
b) an untranslated region (UTR) comprising at least one heterologous UTR element,
wherein the flavivirus a dengue virus,
wherein said LNP comprises: (i) at least one cationic lipid; (ii) a neutral lipid; (iii) a sterol; and (iv) a PEG-lipid.

2. The pharmaceutical formulation according to claim 1 , wherein the at least one encoded polypeptide further comprises a flavivirus non-structural protein or a flavivirus capsid protein (C).

3. The pharmaceutical formulation according to claim 1 , wherein the RNA further comprises a heterologous nucleic acid sequence.

4. The pharmaceutical formulation according to claim 1 , wherein the at least one encoded polypeptide comprises at least one signal sequence, wherein the at least one signal sequence is a signal sequence of a secretory protein or a signal sequence of a membrane protein.

5. The pharmaceutical formulation according to claim 1 , wherein the at least one encoded polypeptide further comprises at least one amino acid sequence; promotes virus-like particle (VLP) formation.

6. The pharmaceutical formulation according to claim 1 , wherein the at least one encoded polypeptide further comprises at least one amino acid sequence that promotes antigen clustering and/or formation of nanoparticles.

7. The pharmaceutical formulation according to claim 2 , wherein the at least one encoded polypeptide further comprises at least one amino acid sequence that promotes self-cleavage of the encoded polypeptide.

8. The pharmaceutical formulation according to claim 1 , wherein the at least one encoded polypeptide comprises a mutated furin cleavage site.

9. The pharmaceutical formulation according to claim 1 , wherein the RNA is an mRNA, which comprises a histone stem-loop, a 3′-UTR element, a 5′-UTR element, a poly(A) sequence, and/or a poly(C) sequence.

10. A kit or kit of parts comprising the pharmaceutical formulation according to claim 1 , and comprising technical instructions providing information on administration and dosage of the components.

11. A method for treating or inhibiting a dengue virus infection comprising administering the pharmaceutical formulation of claim 1 to a patient in need thereof.

12. The pharmaceutical formulation according to claim 5 , wherein the amino acid sequence promoting virus-like particle (VLP) formation is from a hepatitis B virus core antigen.

13. The pharmaceutical formulation according to claim 1 , wherein the coding region comprises a nucleic acid sequence having the coding sequence of SEQ ID NO: 2630.

14. The pharmaceutical formulation according to claim 1 , wherein the coding region encodes a protein that is at least 95% identical to SEQ ID NO: 1101.

15. The pharmaceutical formulation according to claim 14 , wherein the coding region encodes a protein having the sequence of any one of SEQ ID NOs: 1070 and 1097-1103.

16. The pharmaceutical formulation according to claim 14 , wherein the coding region encodes a protein having the sequence of SEQ ID NO: 1101.

17. The pharmaceutical formulation according to claim 1 , wherein the coding region comprises the nucleic acid sequence of any one of SEQ ID NOs: 1375, 1402-1408, 1531, and 1558-1563.

18. The pharmaceutical formulation according to claim 1 , wherein the coding region comprises a nucleic acid sequence having the sequence of SEQ ID NO: 1406 or 1562.

19. The pharmaceutical formulation according to claim 1 , wherein the LNP comprises (i) the cationic lipid; (ii) the neutral lipid; (iii) the sterol; and (iv) the PEG-lipid, in a molar ratio of about 20-60% cationic lipid: 5-25% neutral lipid: 25-55% sterol; and 0.5-15% PEG-lipid.

20. The pharmaceutical formulation according to claim 19 , wherein the PEG-lipid is PEG-DMG or PEG-cDMA.

Assignees

• CureVac SE
• Sanofi Pasteur

Inventors

• Baumhof Patrick
• Grosse Wolfgang
• Jasny Edith
• Kramps Thomas
• Voss Daniel
• Dannenmaier Julia
• Lecouturier Valérie
• Girerd-Chambaz Yves

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61K2039/53

  DNA (RNA) vaccination · CPC title

• A61K2039/575

  humoral response · CPC title